Journal of Assisted Reproduction and Genetics

, Volume 30, Issue 10, pp 1263–1270 | Cite as

Experiences in fertility preservation: lessons learned to ensure that fertility and reproductive autonomy remain options for cancer survivors

  • Nicole Noyes
  • Katherine Melzer
  • Sarah Druckenmiller
  • M. Elizabeth Fino
  • Meghan Smith
  • Jaime M. Knopman
Fertility Preservation



Assess fertility preservation (FP) measures chosen by patients newly diagnosed with malignancy and their outcomes.


Reproductive-age patients referred for FP underwent counseling and elected cryopreservation vs. no treatment. Outcome measures included ovarian stimulation, FP choice, oocytes/zygotes retrieved/cryopreserved and pregnancy outcome.


From 2005 to 2012, 136 patients were counseled with 124 electing treatment: 83 oocyte-only, 21 oocyte + zygote and 20 zygote-only cryopreservation. Age, partnership and financial status factored into FP choice. Treatment was completed in 12 ± 2 days with 14 ± 11 metaphase-II oocytes harvested and cryopreserved/cycle. Eight patients returned to attempt pregnancy; three succeeded.


Our data demonstrate that oocyte and/or zygote banking are feasible FP options for women with malignancy; given the choice, the majority elected oocyte cryopreservation, highlighting desire for reproductive autonomy. Continued growth and research, combined with interdisciplinary communication, will ensure that appropriate candidates are offered FP and the potential for future parenthood, an important quality-of-life marker for survivors.


Cancer survivor Fertility preservation Oocyte cryopreservation Embryo cryopreservation Quality-of-life 



Dr. Noyes would like to acknowledge Dr. Eleonora Porcu of Bologna, Italy for introducing her to oocyte cryopreservation technology and its application as a fertility preservation measure for cancer patients. She also wishes to thank all the oncologists who entrusted her with the FP care of their patients as well as the entire IVF team at the NYULFC, especially Dr. James Grifo and Patti Labella for their efforts in making the oocyte cryopreservation program a success.

Conflicts of interest

None of the authors has a conflict of interest.


  1. 1.
    Azim AA, Costantini-Ferrando M, Oktay M. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Baynosa J, Westphal L, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg. 2009;209:603–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Byrne J, Rasmussen SA, Steinhorn SC, Connelly RR, Myers MH, Lynch CF, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet. 1998;62:45–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Chiva L, Lapuente F, Gonzalez-Cortijo L, Carballo N, Garcia JF, Rojo A, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008;111:S101–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25:2239–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Das M, Shehata F, Son WY, Tulandi T, Holzer H. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy. Hum Reprod. 2012;27:2509–14.PubMedCrossRefGoogle Scholar
  7. 7.
    Diaz J, Sonoda Y, Leitao M, Zivanovic O, Vrown C, Chi D, et al. Oncologic outcome of fertility-sparing radical trachelectomy vs. radical hysterectomy for stage 1B1 cervical carcinoma. Gynecol Oncol. 2008;111:255–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril. 2005;83:897–901.PubMedCrossRefGoogle Scholar
  9. 9.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91.PubMedCrossRefGoogle Scholar
  10. 10.
    Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril. 2001;75:705–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.PubMedGoogle Scholar
  12. 12.
    Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010;93:609–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Han AR, Kwon YS, Kim DY, Kim JH, Kim YM, Kim YT, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009;19:147–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD,, based on November 2011 SEER data submission, posted to the SEER web site, 2012. Website accessed: 1/31/12.
  15. 15.
    Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawana K, Yano T, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. Int J Gynecol Cancer. 2013;23:288–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Knopman JM, Papadopoulos E, Grifo J, Fino ME, Noyes N. Surviving childhood and reproductive age malignancy: effects of treatment on fertility, gametes and future parenthood. Lancet Oncol. 2010;11:490–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Li FP, Fine W, Jaffe N, Holmes GE, Holmes FF. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst. 1979;62:1193–7.PubMedGoogle Scholar
  18. 18.
    Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999;33:66–76.Google Scholar
  19. 19.
    Noyes N, Abu-Rustum N, Ramirez P, Plante M. Options in the management of fertility-related issues after radical trachelectomy in patients with early cervical cancer. Gynecol Oncol. 2009;114:117–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Noyes N, Porcu E, Borini A. With more than 900 babies born, live birth outcomes following oocyte cryopreservation do not appear different from those occurring after conventional IVF. Reprod Biomed Online. 2009;18:769–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Noyes N, Knopman J, Labella P, McCaffrey C, Clark-Williams M, Grifo J. Oocyte cryopreservation outcomes including pre-cryo and post-thaw meiotic spindle evaluation following slow cooling and vitrification of human oocytes. Fertil Steril. 2010;94:2078–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Noyes N, Knopman J, Long K, Coletta J, Abu-Rustum N. Fertility considerations in the management of gynecologic malignancies. Gynecol Oncol. 2011;120:326–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Noyes N, Knopman J, Melzer K, Fino ME, Friedman B, Westphal L. Oocyte cryopreservation as a fertility preservation measure for cancer patients. Reprod Biomed Online. 2011;23:323–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121:136–42.PubMedGoogle Scholar
  26. 26.
    Parmegiani L, Cognigni GE, Bernardi S, Cuomo S, Ciampaglia W, Infante FE, et al. Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes. Reprod Biomed Online. 2011;23:505–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007;43:1646–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Practice Committee of the Society for Assisted Reproductive Technology. Practice Committee of the American Society for Reproductive Medicine: Essential elements of informed consent for elective oocyte cryopreservation: a practice committee opinion. Fertil Steril. 2008;90:S134–5.Google Scholar
  29. 29.
    Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99:37–43.CrossRefGoogle Scholar
  30. 30.
    Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril. 2012;98:1363–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Reh A, Lu L, Weinerman R, Grifo J, Krey L, Noyes N. Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: results of a registry of female cancer patients at 2 years. J Assist Reprod Genet. 2011;28:635–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Rienzi L, Romano S, Albricci L, Maggiulli R, Capalbo A, Baroni E, et al. Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reprod. 2010;25:66–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Ruddy KJ, Partridge AH. The unique reproductive concerns of young women with breast cancer. Adv Exp Med Biol. 2012;732:77–787.PubMedCrossRefGoogle Scholar
  34. 34.
    Rudick B, Opper N, Paulson R, Bendikson K, Chung K. The state of oocyte cryopreservation in the United States. Fertil Steril. 2010;94:2642–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors’ attitudes and experiences. Cancer. 1999;86:530–5.CrossRefGoogle Scholar
  36. 36.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  37. 37.
    Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late affects after allogeneic stem cell transplantation. Blood. 2003;101:3373–85.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang CB, Wang CJ, Huang HJ, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002;94:2192–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Waring AB, Wallace WH. Subfertility following treatment for childhood cancer. Hosp Med. 2000;61:550–7.PubMedGoogle Scholar
  40. 40.
    Werner M, Reh A, Labella P, Noyes N. Laboratory evaluation in oocyte cryopreservation suggests retrieved oocytes are comparable whether frozen for medical indications, deferred reproduction or oocyte donation. J Assist Reprod Genet. 2010;27:613–7.PubMedCrossRefGoogle Scholar
  41. 41. (accessed website 6/26/2012).

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Nicole Noyes
    • 1
  • Katherine Melzer
    • 1
  • Sarah Druckenmiller
    • 2
  • M. Elizabeth Fino
    • 1
  • Meghan Smith
    • 2
  • Jaime M. Knopman
    • 1
  1. 1.Fertility Center at NYU Langone Medical CenterNYU School of MedicineNew YorkUSA
  2. 2.NYU School of MedicineNew YorkUSA

Personalised recommendations